Janssen's BALVERSA receives EC approval for metastatic urothelial carcinoma

By Yahoo! Finance | Aug 26, 2024 at 04:32 AM EST

The European Commission has approved Johnson & Johnson's BALVERSA for treating unresectable or metastatic urothelial carcinoma with specific genetic alterations. The once-daily oral therapy showed significant efficacy in a Phase III clinical trial, offering hope for patients.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.